Detalhe da pesquisa
1.
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Bioorg Chem;
119: 105505, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34838332
2.
Corrigendum to "A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer" [Bioorgan. Chem. 119 (2022) 105505].
Bioorg Chem;
146: 107248, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38458892
3.
Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
Bioorg Med Chem;
20(1): 125-36, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22169601
4.
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Eur J Med Chem;
193: 112232, 2020 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32199135
5.
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
J Med Chem;
61(8): 3454-3477, 2018 04 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29589441
6.
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
J Med Chem;
50(18): 4405-18, 2007 Sep 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17691763
7.
Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
J Med Chem;
49(11): 3101-15, 2006 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16722630
8.
2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Cancer Res;
62(11): 3113-9, 2002 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12036922
9.
Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
J Med Chem;
45(5): 1002-18, 2002 Feb 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11855980
10.
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
J Med Chem;
53(24): 8546-55, 2010 Dec 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21080629
11.
Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
J Med Chem;
52(8): 2265-79, 2009 Apr 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19301902